Capricor Therapeutics Inc (CAPR) Rating Increased to Hold at Zacks Investment Research
Capricor Therapeutics Inc (OTCMKTS:CAPR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Friday.
According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “
Several other equities research analysts also recently weighed in on CAPR. HC Wainwright started coverage on shares of Capricor Therapeutics in a research report on Wednesday, July 6th. They issued a “buy” rating and a $13.00 target price for the company. Roth Capital started coverage on shares of Capricor Therapeutics in a research report on Wednesday, June 15th. They issued a “buy” rating and a $12.00 target price for the company.
Shares of Capricor Therapeutics (OTCMKTS:CAPR) opened at 3.30 on Friday. Capricor Therapeutics has a 12 month low of $1.88 and a 12 month high of $5.40. The stock’s market cap is $59.25 million. The firm has a 50-day moving average price of $3.61 and a 200-day moving average price of $3.58.
Capricor Therapeutics (OTCMKTS:CAPR) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. Equities analysts expect that Capricor Therapeutics will post ($1.04) EPS for the current fiscal year.
In other Capricor Therapeutics news, major shareholder Sinai Medical Center Cedars acquired 312,500 shares of the stock in a transaction that occurred on Wednesday, September 21st. The stock was acquired at an average price of $3.20 per share, with a total value of $1,000,000.00. Following the transaction, the insider now directly owns 2,904,798 shares in the company, valued at $9,295,353.60. The acquisition was disclosed in a document filed with the SEC, which is available through this link.
A hedge fund recently raised its stake in Capricor Therapeutics stock. Sabby Management LLC boosted its position in shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) by 8.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 202,083 shares of the company’s stock after buying an additional 16,419 shares during the period. Sabby Management LLC owned about 1.24% of Capricor Therapeutics worth $513,000 as of its most recent filing with the SEC.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
Receive News & Stock Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related stocks with our FREE daily email newsletter.